Journal
NATURE REVIEWS CANCER
Volume 8, Issue 12, Pages 929-941Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2459
Keywords
-
Categories
Funding
- Cancer Research UK
- Medical Research Council, UK
- British Heart Foundation
- European Union Framework Programme 6 [LSH-2002-2]
- Biotechnology and Biological Sciences Research Council, UK
Ask authors/readers for more resources
Over the last few years disintegrin metalloproteinases of the Adam (a disintegrin and metalloproteinase) family have been associated with the process of proteolytic 'shedding' of membrane-associated proteins and hence the rapid modulation of key cell signalling pathways in the tumour microenvironment. Furthermore, numerous members of the Adam family have been associated with tumorigenesis and tumour progression. The question now arises of whether pharmacological manipulation of their functions would be a useful adjunct to therapies targeting intercellular communications. To learn from the lessons of matrix metalloproteinase inhibitors as anticancer agents, there are many facets of the biological and clinical relevance of the ADAMs that need to be understood before embarking with confidence on such an approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available